secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001125345-23-000045
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics sells TZIELD royalty to DRI for up to $200M; $100M upfront
----------------------------------------------------------------------

- Upfront payment of $100M for single-digit royalty on global net sales of TZIELD.
- MacroGenics retains a 50% share of royalty above an annual threshold.
- Eligible for up to $50M milestone tied to TZIELD advancement in newly diagnosed type 1 diabetes.
- Potential additional $50M if TZIELD achieves a specified net sales level.
- Closing expected March 15, 2023; MacroGenics keeps other regulatory and commercial milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/0001125345-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000045/mgnx-20230308.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer